Evidence-based medicine

102/02/26

Instructor: 鈕聖文醫師, R1羅融

Presenter: Intern 李柏翰

Patient Profile

- Chart No.: 14598379
- Name: 王〇麗
- Gender: female
- Age: 50
- Admission: 102/01/10~02/05

Clinical scenario

- This 50-year-old female had history of:
 - CKD stage 5
 - Old stroke with right hemiparesis
 - Hypertension
 - Left ovarian tumor
- Her last hospitalization was during 101/12/12~
 12/19 due to AV shunt infection s/p removal.
- This time she was admitted for CKD with uremic symptoms, however, during admission, left lower leg pain, tenderness, progressive swelling was noticed since 01/21.

Present Illness

- 1/10 PE: Severe left lower limb non-pitting edema while admission
- Temporary HD with catheter inserted in left iliac vein
- 1/21 Left lower leg pain, tenderness and progressive swelling
- 1/22 CTA: left leg DVT (left external iliac, common femoral, popliteal, ant.&pos. tibial veins, peroneal vein)
 - Heparin → warfarin
 - Consulted CVS/Plasty: kept medical treatment; OP was not considered due to high risk

Present Illness

- 1/25 15pm: Consulted Radiologist: directed thrombolysis; done with urokinase(4.5M IU) under direct access at inguinal femoral vein; infused along left common and external iliac vein + IVC filter placed
 - Kept urokinase dripping with 30K IU/hr
- 1/25 21pm: follow-up left lower extremity venography
- 1/27 17pm: con's change
- 1/27 18pm brain CT: right side ICH
- 2/5 critical AAD

Asking-提出臨床問題

- Background questions
- (1)question
- (2)answer
- (3)apply
- Foreground questions
- (1)PICOT
- (2)search data
- a. Summary
- b. Synopses
- c. Synthesis
- d. Study



Background Question

- What is Post-thrombotic syndrome?
 - pain, swelling, a sensation of heaviness, edema, pigmentation, and deterioration of the skin, and venous ulcers in severe cases.


Foreground question

Patient / Problem	patient with ESRD + DVT	
Intervention	Thrombolysis	
Comparison	Other intervention (such as thrombectomy)	
Outcome	Clot reduction / frequency of adverse event	
Time	Not confined	

Acquire-搜尋最有用的資料

- ■先從已經過評讀的database開始找起 (system, synopses, synthesis)
- ■最後再找尚未經過嚴格評讀的study

Search strategy: 5S model






Grades of Recommendation

Grade of Recommendation	Level of Evidence	Therapy
[A]	1a	Systemic review of RCTs
	1b	Single RCT
	1c	'All-or-none'
[B]	2a	Systemic review of cohort studies
	2b	Cohort study or poor RCT
March Control	2c	'Outcomes' research
	3a	Systemic review of case- control studies
	3b	Case-control study
[C]	4	Case series
[D]	5	Expert opinion, physiology, bench research



Key words: deep vein thrombosis



Treatment of lower extremity DVT

- -- Recommendations UpToDate.
- proximal DVT: treated acutely with (Grade 1A):
 - LMW heparin
 - unfractionated intravenous heparin
 - subcutaneous heparin
 - subcutaneous fondaparinux
- severe renal failure (ClCr<30 mL/min) (Grade 2C):
 - intravenous unfractionated heparin > LMW heparin

Treatment of lower extremity DVT -- Recommendations UpToDate


- IVC filter (Grade 1C) :
 - contraindication to or a failure of anticoagulant therapy
- oral anticoagulation with warfarin (Grade 1A):
 - keep INR target of 2.5 (INR range: 2.0 to 3.0)

Treatment of lower extremity DVT

- -- Recommendations UpToDate
- Anticoagulation failure and massive iliofemoral thrombosis:
 - increasing dosage
 - switching to alternative anticoagulant
 - IVC filter
 - vascular interventions: thrombolytic therapy or thrombectomy
- The selected intervention(s) will depend upon available expertise.



Key words: deep vein thrombosis




Overview of the causes of venous thrombosis



Thrombolysis of DVT-Recommendations

- Thrombolytic therapy + anticoagulation > anticoagulation (Grade 2B):
 - massive iliofemoral or proximal femoral DVT with a high risk of limb gangrene
 - symptomatic for 14 or fewer days
 - do not have an increased risk of bleeding
 - accept the risk of bleeding to potentially obtain relief of acute symptoms and reduced postthrombotic morbidity
- Catheter-directed thrombolysis > systemic thrombolysis (Grade 2C).


Search strategy: 5S model






ACP Journal Club®

- Key word: end-stage renal disease, deep vein thrombosis
 - 查無相關文獻



Search strategy: 5S model






Key word:



- deep vein thrombosis, end stage renal disease
- 無相關的Systemic reviews



Key word:



deep vein thrombosis


	or o	
	Search Manager Medical Terms (MeSH)	
	deep vein thrombosis	
View s	search tips (Word variations have been searched)	
Т	ochrane Database of Systematic Reviews : Issue 1 of 12, January 2013 here are 45 results from 7694 records for your search on 'deep vein thrombosis in titleviews'	tle abst
P	ages 1 - 25 26 - 45	
S	elect all Export all Export selected	
ı	Thrombolysis for acute deep vein thrombosis Lorna Watson and Matthew P Armon July 2004	
_		

Cochrane



- Cochrane review comparing catheterdirected thrombolysis (CDT) for acute DVT with traditional AC in nearly 700 patients revealed the following:
 - Significantly improved early clot lysis with a relative risk reduction of 4.14; 95% CI: 1.22–14.01 to late clot lysis (RR: 2.71; 95% CI: 1.84–3.99).
 - Reduced PTS (RR: 0.66; 95% CI: 0.47–0.94).

Search strategy: 5S model







Cardio Vascular and Interventional Radiology

Title: Catheter-Directed Thrombolysis with Percutaneous Rheolytic Thrombectomy Versus Thrombolysis Alone in Upper and Lower Extremity Deep Vein Thrombosis

Author: Hyun S. Kim et al; Cardiovasc Intervent Radiol (2006) 29:1003-1007

Purpose

 To compare the efficacy of catheter-directed thrombolysis (CDT) alone versus CDT with rheolytic percutaneous mechanical thrombectomy (PMT) for upper and lower extremity deep vein thrombosis (DVT).

Methods

- A retrospective cohort of consecutive patients with acute iliofemoral or brachiosubclavian DVT (symptom duration less than 14 days) treated with urokinase CDT was identified, and a chart review was conducted.
 - 1997~2003
- In patients treated with urokinase CDT alone or combined CDT and rheolytic PMT:
 - Demographic characteristics
 - treatment duration
 - total lytic dose
 - clot lysis rates
 - complications

Thrombolytic technique

- All patients were treated initially with a continuous intravenous infusion of unfractionated heparin,
 - adjusted to maintain aPTT ratio between 2 and 2.5 times control.
- Contraindications to percutaneous thrombolysis:
 - a recent stroke
 - surgery or serious gastrointestinal bleeding
 - a primary or metastatic central nervous system malignancy
 - coagulopathy.

Thrombolytic technique

- CDT with urokinase in 40 limbs from 36 patients
 - 14 men, 22 women; mean age 45.0 years ± 16.3.
- Rheolytic PMT using a 6 Fr Angiojet rheolytic thrombectomy catheter followed by urokinase CDT in 27 limbs from 21 patients
 - 11 men, 10 women; mean age 43.1 years ± 13.8.

Demographic characteristics

Table 1. Patient demographics

	CDT alone $(n = 40)$	CDT and PMT $(n = 27)$	p value
Mean age (years)	45.0 ± 16.3	43.1 ± 13.8	0.656
Gender			
Male	39%	52%	0.322
Female	61%	48%	0.322
Risk factors			
Active cancer	28%	59%	0.009
Thrombophilia	18%	7%	0.238
Previous DVT/PE	23%	26%	0.749
Anatomic risk factor	18%	4%	0.087
Immobilization	5%	11%	0.352
Idiopathic	35%	26%	0.430
Upper extremity limbs treated	35%	30%	0.646
Lower extremity limbs treated	65%	70%	0.646

Thrombophilia, documented biochemical hypercoagulable disorder; Anatomic risk factor, May-Thurner syndrome in lower extremities or thoracic outlet syndrome/effort induced thrombosis in upper extremities; Immobilization, immobilization for longer than 4 weeks prior to onset of DVT; Idiopathic, no identifiable DVT risk factor

Results--Clinical efficacy

The state of the s			
	CDT alone $(n = 40)$	CDT and PMT $(n = 27)$	p value
Treatment duration (hr)	48.0 ± 27.1	26.3 ± 16.6	0.0004
Urokinase doses (million units)	5.6 ± 5.3	2.7 ± 1.8	0.008
Clot reduction			
Grade III Complete lysis	73%	82%	0.395
Grade II 50-99% clot lysis	15%	19%	0.704
Grade I <50%	13%	0	0.056
Stent placements	18%	15%	0.772
Major bleeding	5%	4%	0.803
Minor bleeding	3%	0	0.407
Pulmonary embolism	3%	4%	0.779
ĺ			

Results

- In 67 limbs treated, urokinase CDT with PMT was associated with:
 - 45% reduction in treatment duration
 - **•** (48.0%-26.3%)/48%=45%
 - 52% reduction in total lytic dose;
 - **(**5.6-2.7)/5.6=52%
 - compared with urokinase CDT alone, with a similar safety and efficacy.

CDT alone $(n = 40)$	CDT and PMT $(n = 27)$	p value
48.0 ± 27.1	26.3 ± 16.6	0.0004
5.6 ± 5.3	2.7 ± 1.8	0.008
73%	82%	0.395
15%	19%	0.704
13%	0	0.056
18%	15%	0.772
5%	4%	0.803
3%	0	0.407
3%	4%	0.779
	(n = 40) 48.0 ± 27.1 5.6 ± 5.3 73% 15% 13% 18% 5% 3%	$(n = 40)$ $(n = 27)$ 48.0 ± 27.1 26.3 ± 16.6 5.6 ± 5.3 2.7 ± 1.8 73% 82% 15% 19% 13% 0 18% 15% 5% 4% 3% 0

Conclusion

- Percutaneous CDT with rheolytic PMT is as effective as CDT alone for acute proximal extremity DVT but requires significantly shorter treatment duration and lower lytic doses.
 - Randomized studies to confirm the benefits of pharmacomechanical thrombolysis in the treatment of acute proximal extremity DVT are warranted.

對找到的文章 進行CRITICAL APPRAISAL

Level of evidence

Level	與[治療/預防/病因/危害]有關的文獻	
1a	用多篇RCT所做成的綜合性分析(SR of RCTs)	
1b	單篇RCT(有較窄的信賴區間)	
1c	All or none	
2a	用多篇世代研究所做成的綜合性分析	
2b	單篇cohort及低品質的RCT	
2c	Outcome research / ecological studies	
3a	SR of case-control studies	
3b	Individual case-control studies	
4	Case-series(poor quality : cohort / case-control	
	studies)	
5	沒有經過完整評讀醫學文獻的專家意見	

Validity

- Validity (closeness to the truth):
 - chance (p value, power, confident interval)

bias (selection, measurement, recall

bias)

Table	2.	Clinical	efficacy

	CDT alone	CDT and PMT	n volue
	(n = 40)	(n = 27)	p value
Treatment duration (hr)	48.0 ± 27.1	26.3 ± 16.6	0.0004
Urokinase doses (million units)	5.6 ± 5.3	2.7 ± 1.8	0.008
Clot reduction			
Grade III	73%	82%	0.395
Grade II	15%	19%	0.704
Grade I	13%	0	0.056
Stent placements	18%	15%	0.772
Major bleeding	5%	4%	0.803
Minor bleeding	3%	0	0.407
Pulmonary embolism	3%	4%	0.779

Impact (size of the effect)

	Grade III clot reduction	Major bleeding	
CDT+PMT	82%	4%	EER(Experimental event rate)
CDT	73%	5%	CER(Control event rate)

RRR/RRI (Relative risk reduction/increase)	ARR/ARI (Absolute risk reduction/increase)	NNT/NNH(Number needed to treat/harm)
(CER-EER)/CER; EER-CER/CER	CER-EER; EER - CER	1/ARR; 1/ARI
RRR= (82%-73%) /73%=12% RRI=20%	ARR=9% ARI=1%	NNT=11 NNH=100 LHH=9.09

AAMPICOT for therapy

Item	AAMPICOT for therapy	Comments
Answer	此文獻有沒有回答我的 問題	有
Authors	作者群是這領域的專家 嗎?	是 (Radiologist in Johns Hopkins)
Method	本文獻研究設計是屬於 那一類	Retrospective cohort
Population	取樣是否為隨機取樣?	否
Intervention	給予實驗組的處置是否 描述清楚,並且是臨床 可行的?	足
Comparison	給予對照組的處置是否 描述清楚,並且是臨床 可行的?各種可能比較 皆有了?	部分是

AAMPICOT for therapy

	加目之加其利用八月子用点物	Treatment duration,
Outcome	測量了那些結果?是否用客觀的方式測量?	urokinase dose, clot reduction, adverse
		event
	這些結果是否有統計學上的重要性?	部分有
	這些結果是否有臨床上的重要性?	是
	是否呈現結果的「數值」,「 p值」,「信賴區間」,「檢 力」?	有呈現P值
Time	測量結果的時間點是否合宜?	足
	追蹤時間是否夠長?	是
	文獻發表時間?	2006

Apply

結合醫學倫理方法 將Study的結果應用在病人身上

醫療現況(EBM+臨床專業)	病人意願
50歲女性,ESRD with HD, massive iliofemoral DVT poor response to AC	同意接受CDT並承擔出血風險
生活品質	社會脈絡
CDT能夠減少PTS,改善生活品質	此病人因經濟問題無法選擇PMT治療

Thanks for your attention!